HCPCS drug code · CMS crosswalk
Doxorubicin HCl, Liposomal HCPCS Code
In short
Doxorubicin HCl, Liposomal is billed under HCPCS Q2050 — Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg. One billing unit is 10 mg. CMS's crosswalk lists 24 Doxorubicin HCl, Liposomal NDCs under this code.
Reference
- Q2050
- Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mgBilling unit: 10 mg
- Labelers
- BluePoint Laboratories; Dr. Reddy's Laboratories Inc.; Lupin Pharmaceuticals, Inc.; Northstar RxLLC; Sagent Pharmaceuticals; Sun Pharmaceutical Global FZE.; Zydus Pharmaceuticals (USA) Inc.
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Doxorubicin HCl, Liposomal units and claim line
Enter the dose given to get the Q2050 units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
Doxorubicin HCl, Liposomal NDCs and billing units
From CMS’s ASP NDC–HCPCS crosswalk, effective October 1, 2026 through December 31, 2026. Billing units per package are CMS’s figures for the code’s unit.
| NDC (11-digit) | HCPCS | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| 16714-0742-01 | Q2050 | Northstar RxLLC | 10 | 2 |
| 16714-0856-01 | Q2050 | Northstar RxLLC | 25 | 5 |
| 25021-0263-10 | Q2050 | Sagent Pharmaceuticals | 10 | 2 |
| 25021-0263-25 | Q2050 | Sagent Pharmaceuticals | 25 | 5 |
| 43598-0283-35 | Q2050 | Dr. Reddy's Laboratories Inc. | 10 | 2 |
| 43598-0541-25 | Q2050 | Dr. Reddy's Laboratories Inc. | 25 | 5 |
| 43598-0682-35 | Q2050 | Dr. Reddy's Laboratories Inc. | 10 | 2 |
| 43598-0683-25 | Q2050 | Dr. Reddy's Laboratories Inc. | 25 | 5 |
| 47335-0049-40 | Q2050 | Sun Pharmaceutical Global FZE. | 10 | 2 |
| 47335-0050-40 | Q2050 | Sun Pharmaceutical Global FZE. | 25 | 5 |
| 68001-0345-26 | Q2050 | BluePoint Laboratories | 25 | 5 |
| 68001-0345-36 | Q2050 | BluePoint Laboratories | 10 | 2 |
| 68001-0492-36 | Q2050 | BluePoint Laboratories | 10 | 2 |
| 68001-0493-26 | Q2050 | BluePoint Laboratories | 25 | 5 |
| 68001-0703-36 | Q2050 | BluePoint Laboratories | 10 | 2 |
| 68001-0704-26 | Q2050 | BluePoint Laboratories | 25 | 5 |
| 70710-1530-01 | Q2050 | Zydus Pharmaceuticals (USA) Inc. | 10 | 2 |
| 70710-1531-01 | Q2050 | Zydus Pharmaceuticals (USA) Inc. | 25 | 5 |
| 70748-0339-01 | Q2050 | Lupin Pharmaceuticals, Inc. | 10 | 2 |
| 70748-0340-01 | Q2050 | Lupin Pharmaceuticals, Inc. | 25 | 5 |
| 72603-0103-01 | Q2050 | Northstar RxLLC | 10 | 2 |
| 72603-0200-01 | Q2050 | Northstar RxLLC | 25 | 5 |
| 75907-0363-01 | Q2050 | Dr. Reddy's Laboratories Inc. | 10 | 2 |
| 75907-0364-01 | Q2050 | Dr. Reddy's Laboratories Inc. | 25 | 5 |
Doxorubicin HCl, Liposomal: common questions
- What is the HCPCS code for Doxorubicin HCl, Liposomal?
- Doxorubicin HCl, Liposomal is billed under HCPCS Q2050 — Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg. One billing unit is 10 mg. CMS's crosswalk lists 24 Doxorubicin HCl, Liposomal NDCs under this code.
- How many Q2050 billing units are in a package of Doxorubicin HCl, Liposomal?
- CMS lists 2 to 5 billing units per package, depending on the NDC, where one unit is 10 mg. Units to report are based on the dose given, not the package.
- Is Q2050 a CPT code?
- No. Q2050 is a HCPCS Level II code from CMS for the drug itself. Giving it, for example by injection or infusion, is usually reported with a separate CPT administration code.